SCYNEXIS Applauds the Biomedical Advanced Research and Development Authority (BARDA) for Its New Priority Focus on Investment in Development of Antifungal Treatments to Fight Infections Caused by Drug-Resistant Fungal Threats
JERSEY CITY, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today applauded action taken this week by the Biomedical Advanced Research and Development Authority (BARDA) to add to the areas of interest in its new Broad Agency Announcement (BAA) the development of antifungal Medical Countermeasures (MCM) to treat infections caused by drug-resistant fungal threats. For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.
Related news for (SCYX)
- SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
- SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update
- SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections
- scynexis to present preclinical data on second generation fungerp scy-247 at idweek 2024
- SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference